Summary:
Phase 3 study involving GLP agonist like Ozempic plus second agent vs Monjuaro as add on therapy to metformin plus or minus jardiance or farxiga in patients with type 2 diabetes who are not adequately controlled on current therapy. The study will last 76 weeks.
Criteria:Have Type 2 Diabetes
Hemoglobin A1c greater than 7.0
BMI greater than 27
On Metformin plus or minus Jardaince or Farxiga